Compounded vs Brand Injectable Semaglutide: True Cost-of-Ownership Comparison
The compounded vs brand-name semaglutide comparison is often reduced to monthly price. The true cost-of-ownership analysis is more layered. Here's the full picture.
The Headline Price
| Attribute | Compounded | Brand (NovoCare) |
|---|---|---|
| Typical monthly cost | $149-$299 | ~$199 intro / $349 ongoing |
| First 12-month cost | $1,800-$3,600 | ~$3,388 |
| Prior authorization needed? | No | Yes (if insurance) |
| Refill continuity risk | Moderate | Low |
| FDA-approved product | No | Yes |
| Insurance covered? | No (cash only) | Sometimes |
Embody
Injectable semaglutide only — lead compounded option.
- Injectable semaglutide focus
- Standard titration
- Direct pharmacy shipping
Wellorithm
Compounded GLP-1 with dose-tier pricing.
- Sema and tirz options
- Tier pricing by dose
- Verify at intake
Hidden Costs on Each Side
Compounded hidden costs: potential mid-treatment provider switches (fees, transition friction), pharmacy shutdowns requiring re-establishment elsewhere, occasional API supplier changes affecting quality perception. These aren't necessarily out-of-pocket cash costs, but they represent real friction.
Brand hidden costs: prior authorization time and delays, potential coverage denials requiring appeals, occasional supply chain issues at partner pharmacies, and copays that vary widely by insurance plan even for "covered" prescriptions.
Telos Rx
Compounded tirzepatide via direct pharmacy.
- Compounded tirzepatide
- Direct-link intake
- Verify pricing
MadeMed
Independent compounder — sema, tirz, and oral formats.
- Compounded sema/tirz
- Oral tirz $167-229
- Direct pharmacy fulfillment
Continuity Risk
Brand-name pathways carry minimal continuity risk from the manufacturer side — Novo isn't going to stop making Wegovy. The main brand-continuity risks are insurance coverage changes and prior authorization requirements that can shift year to year.
Compounded pathways carry continuity risk from provider consolidation, regulatory action, and platform-level operational issues. This has been real over the past 18 months and is worth factoring in when comparing total ownership cost.
Oak Weight Loss
Telehealth program with compounded GLP-1 access.
- Compounded GLP-1
- Standard intake
- Membership pricing
Personalization
Compounded's advantage is dose flexibility outside brand strengths. Patients who need 0.35 mg weekly (between brand 0.25 and 0.5 tiers), slower titration schedules, or combination formulations (semaglutide + B12) can access these through compounding. Brand-name is limited to the strengths and formulations Novo produces commercially.
For patients on standard doses (0.25, 0.5, 1.0, 1.7, 2.4 mg), personalization isn't a factor. For patients needing off-standard dosing, it's a decisive factor.
SHED
Note: SHED's price jumps to $399/mo at 7.5mg+.
- Lower entry pricing
- Price jump at 7.5mg+
- Compounded sema + tirz
The Honest Decision
Compounded wins on: raw price, personalization, dose flexibility, and access when insurance denies brand-name coverage. Brand wins on: continuity, FDA-approved product, insurance coverage (when available), and simpler total picture. Choose based on which factors matter most to your situation, not on marketing framing from either side.
Sesame Care
Marketplace for brand-name FDA-approved GLP-1 only.
- Brand-name only
- Direct consult marketplace
- Cash-pay clarity
Found Health
Brand-name GLP-1 access with coaching layer.
- Brand-name focus
- Coaching + accountability
- Insurance-coordinated
Where to Start
Embody
Injectable semaglutide only — lead compounded option.
- Injectable semaglutide focus
- Standard titration
- Direct pharmacy shipping
Wellorithm
Compounded GLP-1 with dose-tier pricing.
- Sema and tirz options
- Tier pricing by dose
- Verify at intake
MadeMed
Independent compounder — sema, tirz, and oral formats.
- Compounded sema/tirz
- Oral tirz $167-229
- Direct pharmacy fulfillment